Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared HolzПодробнее

Blocking the Horizon-Amgen deal will be worse for pharma than for biotech, says Mizuho's Jared HolzПодробнее

Weight loss drug market is just beginning to take off, says Mizuho's Jared HolzПодробнее

Expectations for Pfizer have been low, says Mizuho's Jared Holz on weight-loss pill setbackПодробнее

The Caltech Effect: Analyzing 3 Billion Proteins to Diagnose DiseaseПодробнее

The direction of M&A in biotech is very, very vast, says Oppenheimer's HolzПодробнее

Nobody was expecting a 27% margin guide from Salesforce, says Mizuho's Greg MoskowitzПодробнее

Pfizer is far behind weight loss drug race despite pill trial, says Mizuho's Jared HolzПодробнее

Biogen has been an 'uninvestable' stock for awhile, says Mizuho's Jared HolzПодробнее

Mizuho's Jared Holz on finding opportunities in the biotech spaceПодробнее

The Smart Surface - monitoring cells for treatmentПодробнее

Trader says weakness in tech stocks not a correction, there's just more dispersionПодробнее

Jackson Hole Symposium; What does it mean for the markets & macro | Ryan Sweet to ET NOWПодробнее

Sox17 and future research studies 9 of 9Подробнее

Brain protein deciphered at Advanced Light SourceПодробнее

Mimi Huizinga, Novartis - 2019 Stanford Medicine Big Data | Precision HealthПодробнее

Article Marketing: Mostly A Scam - Whiteboard FridayПодробнее

Revolutionize your marketing strategy!Подробнее

Mark Traphagen - Becoming Better SEO Scientists - Whiteboard FridayПодробнее

Chapter Seven: Optimise for Flow (Quarter 2) .3 - Organisational MasteryПодробнее